Morten Rytter Tulstrup

Morten Rytter Tulstrup serves as a Lecturer in the Department of Public Health within the Faculty of Health and Medical Sciences at the University of Copenhagen. His academic affiliation centers on the Section of Biostatistics, where he conducts research at the intersection of hematology, epidemiology, and pharmacovigilance. His institutional address is Øster Farimagsgade 5 opg. B, 1353 København K.

His research spans hematological malignancies, clonal hematopoiesis, and drug safety assessment. Key focus areas include:

• Mendelian randomization studies for causal inference in testosterone therapy
• DNA methylation alterations in myelodysplastic syndromes
• Epidemiological patterns of anabolic steroid complications
• Clonal evolution in multiple myeloma and acute leukemias
• Pharmacovigilance methodologies for adverse drug reactions

His work integrates genomic, epigenetic, and population-level data to address clinical questions in hemato-oncology.

Analysis of his 16 recent publications (2023-2025) reveals consistent focus on hematological disorders with emerging emphasis on Mendelian randomization techniques. His collaborative network spans Danish hospitals and international consortia, particularly in studies involving large population cohorts and genomic databases. Key publication venues include Leukemia, Haematologica, and specialized pharmacology journals.

No scientific awards are currently documented in available sources. His research impact is evidenced by social media dissemination across X (formerly Twitter), Bluesky, and Mendeley readership, with several studies picked up by news outlets.

Tulstrup participates in multi-institutional collaborations, notably with Rigshospitalet and Copenhagen University Hospital departments. His current work involves Danish population-based studies on clonal hematopoiesis (e.g., COVID-19 hospitalization research) and testosterone-related adverse events. He appears integrated within the university's hematology research ecosystem but no dedicated lab leadership is indicated.